


7: Niethammer AG, Xiang R, Ruehlmann JM, Lode HN, Dolman CS, Gillies SD, Related Articles Reisfeld RA. Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma. Cancer Res. 2001 Aug 15;61(16):6178-84. PMID: 11507070 [PubMed - indexed for MEDLINE] 18: Xiang R, Silletti S, Lode HN, Dolman CS, Ruehlmann JM, Niethammer AG, Pertl Related Articles U, Gillies SD, Primus FJ, Reisfeld RA. Protective immunity against human carcinoembryonic antigen (CEA) induced by an oral DNA vaccine in CEA-transgenic mice. Clin Cancer Res. 2001 Mar;7(3 Suppl):856s-864s. PMID: 11300483 [PubMed - indexed for MEDLINE] 19: Imboden M, Murphy KR, Rakhmilevich AL, Neal ZC, Xiang R, Reisfeld RA, Related Articles Gillies SD, Sondel PM. The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy. Cancer Res. 2001 Feb 15;61(4):1500-7. PMID: 11245457 [PubMed - indexed for MEDLINE] 10: Beecken WD, Fernandez A, Joussen AM, Achilles EG, Flynn E, Lo KM, Gillies Related Articles SD, Javaherian K, Folkman J, Shing Y. Effect of antiangiogenic therapy on slowly growing, poorly vascularized tumors in J Natl Cancer Inst. 2001 Mar 7;93(5):382-7. PMID: 11238700 [PubMed - indexed for MEDLINE] 11: Dezube BJ, Dahl TA, Wong TK, Chapman B, Ono M, Yamaguchi N, Gillies SD, Related Articles Chen LB, Crumpacker CS. A fusion inhibitor (FP-21399) for the treatment of human immunodeficiency virus infection: a phase I study. J Infect Dis. 2000 Aug; 182(2):607-10. PMID: 10915097 [PubMed - indexed for MEDLINE] **Related Articles** 12: Lode HN, Xiang R, Gillies SD, Reisfeld RA. Amplification of T cell-mediated immune responses by antibody-cytokine fusion proteins. Immunol Invest. 2000 May;29(2):117-20. No abstract available. PMID: 10854178 [PubMed - indexed for MEDLINE] 13: Lode HN, Xiang R, Pertl U, Forster E, Schoenberger SP, Gillies SD, Reisfeld Related Articles Melanoma immunotherapy by targeted IL-2 depends on CD4(+) T-cell help mediated by CD40/CD40L interaction. J Clin Invest. 2000 Jun; 105(11):1623-30. PMID: 10841521 [PubMed - indexed for MEDLINE] Related Articles 14: Batova A, Kamps A, Gillies SD, Reisfeld RA, Yu AL. The Ch14.18-GM-CSF fusion protein is effective at mediating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro. Clin Cancer Res. 1999 Dec;5(12):4259-63. PMID: 10632368 [PubMed - indexed for MEDLINE]

15: Xiang R, Lode HN, Gillies SD, Reisfeld RA.	Related Articles
T cell memory against colon carcinoma is long-lived in the absence J Immunol. 1999 Oct 1;163(7):3676-83.	e of antigen.
PMID: 10490962 [PubMed - indexed for MEDLINE]	
16: Kendra K, Gan J, Ricci M, Surfus J, Shaker A, Super M, Frost JD, Rakhmile A, Hank JA, Gillies SD, Sondel PM.	
Pharmacokinetics and stability of the ch14.18-interleukin-2 fusion Cancer Immunol Immunother. 1999 Aug;48(5):219-29. PMID: 10478638 [PubMed - indexed for MEDLINE]	protein in mice.
SD, Reisfeld RA.	cles, Free in PMC
Tumor-targeted IL-2 amplifies T cell-mediated immune response i therapy with single-chain IL-12. Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8591-6. PMID: 10411920 [PubMed - indexed for MEDLINE]	nduced by gene
□ 18: Gillies SD, Lan Y, Lo KM, Super M, Wesolowski J.	Related Articles
Improving the efficacy of antibody-interleukin 2 fusion proteins by interaction with Fc receptors. Cancer Res. 1999 May 1;59(9):2159-66. PMID: 10232603 [PubMed - indexed for MEDLINE]	y reducing their
19: Gan J, Kendra K, Ricci M, Hank JA, Gillies SD, Sondel PM.	Related Articles
Specific enzyme-linked immunosorbent assays for quantitation of fusion proteins. Clin Diagn Lab Immunol. 1999 Mar;6(2):236-42. PMID: 10066660 [PubMed - indexed for MEDLINE]	antibody-cytokine
20: Lin L, Gillies SD, Schlom J, Pestka S.	Related Articles
Construction of phosphorylatable chimeric monoclonal antibody (kinase I recognition site. Protein Expr Purif. 1999 Feb;15(1):83-91. PMID: 10024474 [PubMed - indexed for MEDLINE]	CC49 with a casein
Display Summary V Sort V Save Text Clip Add	Order:

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Freedom of Information Act | Disclaimer

1686-po-limor-gm: 18116 2002 16 34:53




Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Freedom of Information Act | Disclaimer

1000 p. Anex-gra 1 d.16 2602 1604 53









8: Hank JA, Surfus JE, Gan J, Jaeger P, Gillies SD, Reisfeld RA, Sondel PM.

Related Articles

Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2).

Clin Cancer Res. 1996 Dec;2(12):1951-9.

PMID: 9816154 [PubMed - indexed for MEDLINE]

9: Albertini MR, Hank JA, Schiller JH, Khorsand M, Borchert AA, Gan J, Bechhofer Related Articles R, Storer B, Reisfeld RA, Sondel PM.

Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients.

Clin Cancer Res. 1997 Aug;3(8):1277-88.

PMID: 9815810 [PubMed - indexed for MEDLINE]

✓ 10: Sondel PM, Hank JA.

Related Articles

Combination therapy with interleukin-2 and antitumor monoclonal antibodies.

Cancer J Sci Am. 1997 Dec;3 Suppl 1:S121-7. Review.

PMID: 9457407 [PubMed - indexed for MEDLINE]

✓ 11: Lode HN, Xiang R, Varki NM, Dolman CS, Gillies SD, Reisfeld RA.

Related Articles

Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow.

J Natl Cancer Inst. 1997 Nov 5;89(21):1586-94.

PMID: 9362156 [PubMed - indexed for MEDLINE]

12: Albertini MR, Gan J, Jaeger P, Hank JA, Storer B, Schell K, Rivest T, Surfus J, Related Articles Reisfeld RA, Schiller JH, Sondel PM.

Systemic interleukin-2 modulates the anti-idiotypic response to chimeric anti-GD2 antibody in patients with melanoma.

J Immunother Emphasis Tumor Immunol. 1996 Jul;19(4):278-95.

PMID: 8877722 [PubMed - indexed for MEDLINE]

13: Becker JC, Pancook JD, Gillies SD, Mendelsohn J, Reisfeld Related Articles, Free in PMC RA.

Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins.

Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2702-7.

PMID: 8610104 [PubMed - indexed for MEDLINE]

114: Pancook JD, Becker JC, Gillies SD, Reisfeld RA.

Related Articles

Eradication of established hepatic human neuroblastoma metastases in mice with severe combined immunodeficiency by antibody-targeted interleukin-2.

Cancer Immunol Immunother. 1996 Feb;42(2):88-92.

PMID: 8620525 [PubMed - indexed for MEDLINE]

15: Sabzevari H, Gillies SD, Mueller BM, Pancook JD, Reisfeld Related Articles, Free in PMC RA.

A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice.

Proc Natl Acad Sci U S A. 1994 Sep 27;91(20):9626-30. PMID: 7937818 [PubMed - indexed for MEDLINE]

16: Gillies SD, Young D, Lo KM, Roberts S.

Related Articles

Biological activity and in vivo clearance of antitumor antibody/cytokine fusion

proteins.

Bioconjug Chem. 1993 May-Jun;4(3):230-5.

PMID: 8324014 [PubMed - indexed for MEDLINE]

17: Gillies SD, Reilly EB, Lo KM, Reisfeld RA.

Related Articles, Free in PMC

8,000 3800 Stroke 8 (32 29 2002 10 24 DE

Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells.

Proc Natl Acad Sci U S A. 1992 Feb 15;89(4):1428-32. PMID: 1741398 [PubMed - indexed for MEDLINE]



Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Freedom of Information Act | Disclaimer

8/21/02 3:35 PM